Efficacy of adjunctive Celecoxib in improvement of Obsessive-compulsive disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201512235280N21

Enrollment

Registered

2016-01-05

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: In case group SSRI plus celecoxib 400 mg/day (200 mg bid). Intervention 2: placebo group SSRI plus placebo in same shape and dose.

Treatment - Drugs

In case group SSRI plus celecoxib 400 mg/day (200 mg bid).

placebo group SSRI plus placebo in same shape and dose.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion: Patients were considered for participation in the project if they were met DSM-1V criteria for diagnosis of OCD. The diagnosis was confirmed by a psychiatrist based on structured interview ; A minimum score of 21 or above on the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS). Exclusion: The patients did not receive any Psychotropic medications such as selective serotonin reuptake inhibitors (SSRIs), tricyclic Antidepressants (TCAs), or monoamine oxide inhibitors for 4 weeks preceding entry into the trial Patients; they suffered from known autoimmune disease; bipolar I or bipolar II disorder; eating disorders; personality disorders; mental retardation; substance dependence or abuse; had a concurrent medical illness; history of seizures that would contraindicate use of the study medication; receiving ECT; peptic ulcers or a history of gastrointestinal bleeding; use of any medications identified as contra-indicated with COX-2 inhibitors.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obsessive-compulsive disorder. Timepoint: baseline, 4, 8, 12 weeks. Method of measurement: Yale–Brown Obsessive–Compulsive Scale (Y-BOCS).;Depression. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Depression Rating Scale.;Anxiety. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Anxiety Rating Scale.;Illness severity. Timepoint: Baseline, 1, 2, 3,4 weeks. Method of measurement: Clinical Global Impression (CGI).	—

Measure

Time frame

Obsessive-compulsive disorder. Timepoint: baseline, 4, 8, 12 weeks. Method of measurement: Yale–Brown Obsessive–Compulsive Scale (Y-BOCS).;Depression. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Depression Rating Scale.;Anxiety. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Anxiety Rating Scale.;Illness severity. Timepoint: Baseline, 1, 2, 3,4 weeks. Method of measurement: Clinical Global Impression (CGI).

—

Secondary

Measure	Time frame
Side Effect. Timepoint: baseline, 4, 8, 12 weeks. Method of measurement: Check List.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Najmeh Shahini

Mashhad University of Medical sciences

shahinin921@mums.ac.ir+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026